DOACs vs. Warfarin for OPRA: Selection, Dosing, Reversal and MCQs

Mechanism and why monitoring differs

Warfarin inhibits vitamin K epoxide reductase, reducing hepatic synthesis of clotting factors II, VII, IX and X — because it acts upstream on synthesis rather than on a single circulating factor, its effect takes days to establish and fluctuates with diet, other drugs and liver function, which is why routine INR monitoring is required. DOACs act as direct inhibitors of a single active clotting factor — dabigatran directly inhibits thrombin (factor IIa); apixaban, rivaroxaban and edoxaban directly inhibit factor Xa. Because a DOAC's effect is predictable from the dose alone rather than varying with diet or minor interactions, routine coagulation monitoring isn't required for standard dosing.

Indication-based dosing (illustrative — always confirm against current product information)

• Non-valvular atrial fibrillation: apixaban 5 mg twice daily (2.5 mg twice daily if ≥2 dose-reduction criteria met — age ≥80, weight ≤60 kg, creatinine ≥133 micromol/L); rivaroxaban 20 mg once daily with food (15 mg if CrCl 15–49 mL/min); dabigatran 150 mg twice daily (110 mg twice daily in selected higher-bleeding-risk patients).
• Treatment of venous thromboembolism (VTE): most DOACs use a higher initial dose for the first 1–3 weeks before stepping down to a maintenance dose — a common exam trap when a stem asks about "the" rivaroxaban or apixaban dose without specifying which phase of treatment.
• Warfarin: dosed to a target INR range (commonly 2–3 for AF and VTE; higher, e.g. 2.5–3.5, for select mechanical heart valve indications) rather than to a fixed mg dose — individual maintenance doses vary widely between patients.

Why warfarin still has a place

DOACs are not used with mechanical heart valves or in moderate-to-severe mitral stenosis — warfarin remains the standard in both settings, and this is one of the most consistently tested "DOACs aren't always the answer" facts on OPRA. Warfarin is also often preferred in severe renal impairment, where DOAC clearance and accumulation become less predictable — but this is a simplification useful for OPRA revision rather than a fixed rule: the actual choice depends on the specific indication, the degree of impairment, and current Australian guidance, so always check current product information and Therapeutic Guidelines rather than treating "severe renal impairment" alone as an automatic warfarin trigger.

Renal function drives the DOAC decision, not just the dose

Unlike warfarin, which is hepatically metabolised and largely unaffected by renal function, DOACs are cleared renally to varying degrees (dabigatran the most, apixaban the least) — a falling CrCl can move a patient from "reduce the dose" to "avoid this class entirely," and OPRA scenarios that give a low CrCl alongside a DOAC are usually testing exactly that threshold, not just a dose adjustment.

Switching between anticoagulants

• Warfarin → DOAC: stop warfarin and start the DOAC once the INR has fallen to an appropriately low level (commonly below 2, drug-specific — check current product information), to avoid a period of over-anticoagulation from the two agents overlapping.
• DOAC → warfarin: because warfarin takes days to become effective, the DOAC is generally continued in parallel with warfarin until the INR is within the therapeutic range, then stopped — the opposite pattern to the warfarin→DOAC switch, and a common source of confusion in exam stems.
• Interrupting a DOAC for surgery: timing depends on the drug's renal clearance, the patient's renal function, and the bleeding risk of the procedure — there's no single fixed interval that applies to every DOAC and every patient.

Perioperative DOAC interruption — the two axes that decide timing

There's no single stop-before-surgery interval that applies across the board — the decision runs along two independent axes that combine to set the interval: how much bleeding risk the procedure itself carries, and how well the drug is being cleared. A high-bleeding-risk procedure needs a longer interruption than a low-bleeding-risk one for the same drug; reduced renal function extends the interval further because clearance is slower, so the drug takes longer to fall to a level considered safe for surgery. OPRA scenarios that give both a procedure type and a renal function are testing whether you apply both axes together, not just one.

Reversal in a bleeding patient

Warfarin reversal is well established: vitamin K for non-urgent reversal, and prothrombin complex concentrate (with vitamin K) for major bleeding needing rapid correction. DOAC reversal is agent-specific — idarucizumab is a targeted reversal agent for dabigatran; andexanet alfa is available in some settings for factor Xa inhibitors (apixaban, rivaroxaban), though access varies and general supportive measures plus prothrombin complex concentrate may be used where a targeted agent isn't available. Recognising that DOAC reversal is not simply "give vitamin K" — that's specific to warfarin — is a frequently tested distinction.

Why don't DOACs need routine monitoring the way warfarin does?

DOACs directly and predictably inhibit a single clotting factor at a fixed dose, so their anticoagulant effect doesn't vary the way warfarin's does with diet, liver function and other drug interactions — which is why warfarin needs regular INR monitoring and DOACs generally don't for standard dosing.

Can DOACs be used with a mechanical heart valve?

No. Mechanical heart valves (and moderate-to-severe mitral stenosis) remain warfarin-only indications — DOAC trials excluded these patients and showed worse outcomes when tried, so warfarin stays the standard of care in this setting.